Search clinical trials for: Lowering high cholesterol

Total 23587 results

Yonsei University

Not yet recruiting

Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)

Peripheral Artery Disease | Polyvascular Disease

Korea, Republic of
University of Roehampton

Recruiting

Efficacy of Cholesterol-lowering L. Plantarum on Cardiometabolic Health Biomarkers in Coeliac Disease Patients (ProCoChoL)

Celiac Disease

Italy, United Kingdom
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

Dyslipidemia

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Czechia, Hungary, Taiwan, Colombia, Poland, Russian Federation, Switzerland, Korea, Republic of, Mexico, ... and more
Organon and Co

Completed

A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)

Hypercholesterolemia
Organon and Co
Merck Shering-Plough JV Study

Completed

A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)

Hypercholesterolemia
Amgen

Active, not recruiting

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

Coronary Heart Disease (CHD)

Canada, France, United States, Spain, United Kingdom, Korea, Republic of, Netherlands, Austria, Australia, Czechia, Taiwan, Finland, Hungary, Italy, Poland, Greece, Germany, Brazil, Latvia, Denmark, Mexico, Russian Federation, Bulgaria and more
GWT-TUD GmbH

Active, not recruiting

Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry (PERI-DYS)

Dyslipoproteinemias

Germany
Unity Health Toronto
University of Manitoba; University of British Columbia; Canadian Institutes of... and other collaborators

Completed

The Combined Portfolio Diet and Exercise Study (PortfolioEx)

Cardiovascular Diseases | Metabolic Syndrome | Type 2 Diabetes | Hypercholesterolemia

Canada
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension (FOURIER OLE)

Dyslipidemia

United States, Poland, Czechia, Hungary, Russian Federation, Ukraine, Slovakia
Amgen

Terminated

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia

China
University of Alberta

Completed

Kefir Cholesterol Lowering Pilot Study

Hypercholesterolemia

Canada
Aarhus University Hospital
HeartFlow, Inc.

Completed

Influence of Lipid Lowering on Impaired Coronary Flow

Coronary Artery Disease

Denmark
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Hyperlipidemia

United States, Denmark, Taiwan, Korea, Republic of, Australia, Belgium, Canada, South Africa, France, Turkey
Amgen

Completed

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Hyperlipidemia

United States, Denmark, France, Italy, Czechia, Taiwan, Switzerland, Korea, Republic of, Germany, Hong Kong, Netherlands, Australia, Belgium, Canada, Hungary, South Africa, Russian Federation, Spain, United Kingdom, Sweden, Mexico
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels (MENDEL)

Hyperlipidemia

United States, Denmark, Australia, Belgium, Canada
Matthew Feinstein

Completed

High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV (HILLCLIMBER)

HIV Infection | Coronary Heart Disease

United States
Ukrainian Medical Stomatological Academy

Completed

Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease (EFFORT)

Adverse Effect | Atherosclerosis, Coronary | Insulin Resistance Syndrome

Ukraine
Organon and Co

Completed

Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)

Hypercholesterolemia
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge

Active, not recruiting

Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease (INTENSITY-HIGH)

Cardiovascular Diseases | Atherosclerosis

United Kingdom
Cliniques universitaires Saint-Luc- Université...

Withdrawn

Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy

Patients With High Cholesterol Levels Needing a Lipid-lowering Therapy

Belgium
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol

Dyslipidemias

Belgium
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol (LA ATGOAL)

Dyslipidemias

Brazil, Colombia, Panama, Mexico, Guatemala, Chile, Ecuador, Venezuela
Beijing Anzhen Hospital

Unknown

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD) (FORWARD)

Dyslipidemia | High Risk Coronary Artery Disease

China
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 (GAUSS-4)

Hypercholesterolemia

Japan
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 (GAUSS-2)

Hyperlipidemia

United States, Denmark, Belgium, Germany, Hong Kong, Netherlands, France, Australia, Canada, South Africa, United Kingdom, Spain, Poland, Switzerland
Amgen

Completed

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 (RUTHERFORD-2)

Hyperlipidemia

Canada, France, Netherlands, United Kingdom, New Zealand, South Africa, Spain, United States, Australia, Germany, Sweden, Hong Kong, Switzerland, Norway
Yonsei University

Unknown

RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)

Cardiovascular Diseases | Cerebrovascular Disease | Peripheral Atherosclerotic Disease

Korea, Republic of
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Hyperlipidemia

Canada, Denmark, France, United States, Czechia, New Zealand, Australia, South Africa, Italy, United Kingdom, Netherlands, Germany, Norway
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)

Coronary Artery Disease | Atherosclerosis | Carotid Artery Diseases

United States, Canada
Amgen

Completed

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)

Dyslipidemia

United States, Belgium, Denmark, Finland, France, Italy, Spain, Hungary, Poland, Germany, Czechia, Turkey, United Kingdom, Malaysia, Australia, Hong Kong, New Zealand, Canada, South Africa, Greece, Portugal, Netherlands, Russian Federation and more
Unity Health Toronto
University of Manitoba; University of British Columbia; Canadian Institutes of... and other collaborators

Withdrawn

Magnetic Resonance Imaging-Portfolio Diet Study #7 (MRIPD#7)

Cardiovascular Diseases | Obesity | Diabetes | Metabolic Syndrome | Hypercholesterolemia

Canada
Unity Health Toronto
University of Manitoba; University of British Columbia; Canadian Institutes of... and other collaborators

Withdrawn

Enhanced Multicenter Dietary Portfolio Study (EDP8)

Cardiovascular Diseases | Type 2 Diabetes | Hypercholesterolemia

Canada
Listen Trial Group

Completed

LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts (LISTEN)

Hypercholesterolemia With Concomitant Type 2 Diabetes

Japan
University of Jena
German Federal Ministry of Education and Research

Completed

Cholesterol-lowering Effects of Lupin Protein

Hypercholesterolemia

Germany
Chinese Academy of Medical Sciences, Fuwai Hospital

Unknown

Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients (CHIEF)

Essential Hypertension

China
AstraZeneca

Completed

An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon (CEPHEUS)

High Blood Cholesterol
Odense University Hospital

Completed

Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment

Myocardial Infarction [C14.907.585.500]

Denmark
Kowa Research Europe

Completed

Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels

Dyslipidemia | Primary Hypercholesterolemia

Spain, Denmark, India, Israel, Sweden, Finland, Germany, Italy, Netherlands, Norway, Poland, Russian Federation, United Kingdom
AstraZeneca

Completed

Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia

Hypercholesterolemia
McGill University Health Centre/Research Institute...

Completed

High-Density Lipoprotein (HDL) Treatment Study

Genetic Diseases, Inborn | Coronary Arteriosclerosis | Hypoalphalipoproteinemias

Canada
University of Saskatchewan
Heart and Stroke Foundation of Canada

Completed

Exercise and Flax-Based Nutritional Supplementation for Lowering Cholesterol

Metabolic Syndrome | Osteoporosis

Canada
Cedars-Sinai Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

Prostate Cancer
Novartis Pharmaceuticals

Not yet recruiting

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

Hypercholesterolemia
Fundació Eurecat
University Rovira i Virgili

Not yet recruiting

Effect of a Grape Seed Proanthocyanidin Extract (GSPE) on LDL Cholesterol Levels in Rotating Night Shift Workers (CIRCAFENOL)

Cardiovascular Diseases | Cholesterol Level, High | Circadian Rhythm Sleep Disorder, Shift Work Type

Spain
University of Salerno

Not yet recruiting

Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients (BESAFE)

Cardiovascular Diseases | Dyslipidemias | Lipid Metabolism Disorders | Statin Adverse Reaction
University of Tennessee
Sponsor GmbH

Recruiting

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence (MedAAAction)

Depression | Coronary Artery Disease | Stroke | Hypertension | Diabetes | Chronic Kidney Diseases | Anxiety | Chronic Lung Disease | Pulmonary Embolism | Congestive Heart Failure | Arrythmia | Heart Attack | High Cholesterol/Hyperlipidemia

United States
University of Bergen
The Norwegian Seafood Research Fund

Not yet recruiting

Effect of Herring Oil Concentrate on LDL Cholesterol Concentration in Adults

High Cholesterol

Norway
Rowan University

Recruiting

Project WHADE: A Partner-Based Physical Activity Program for Women

Smoking | Hypertension | Metabolic Syndrome | PreDiabetes | Prehypertension | Type 2 Diabetes | High Cholesterol

United States
Eli Lilly and Company

Recruiting

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Elevated Lp(a) | Atherosclerotic Cardiovascular Disease (ASCVD)

United States, Australia, Spain, Canada, Argentina, China, Italy, France, Japan, Taiwan, Korea, Republic of, Denmark, Germany, Hungary, Israel, Austria, Belgium, Netherlands, Brazil, Mexico, Romania, United Kingdom, Greece, Czechia, Poland and more
Novartis Pharmaceuticals

Not yet recruiting

VictORION-INCLUSION is a Multicenter, Randomized, Open Label, Study of Inclisiran + Usual Care vs Usual Care Alone in an Inclusive and Underrepresented Population at High Risk for or Diagnosed With ASCVD Within a Pragmatic EHR Framework. (V-INCLUSION)

Atherosclerotic Cardiovascular Disease

Search clinical trials for: Lowering high cholesterol

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations